IGHSX
Price
$12.43
Change
-$0.02 (-0.16%)
Updated
Jun 2 closing price
Net Assets
348.37M
TEDRX
Price
$30.62
Change
-$0.05 (-0.16%)
Updated
Jun 2 closing price
Net Assets
9.15B
Interact to see
Advertisement

IGHSX vs TEDRX

Header iconIGHSX vs TEDRX Comparison
Open Charts IGHSX vs TEDRXBanner chart's image
IGHSX vs TEDRX Comparison Chart in %
View a ticker or compare two or three
VS
IGHSX vs. TEDRX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IGHSX is a Buy and TEDRX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
TEDRX has more cash in the bank: 9.15B vs. IGHSX (348M). IGHSX pays higher dividends than TEDRX: IGHSX (1.66) vs TEDRX (1.40). IGHSX was incepted earlier than TEDRX: IGHSX (18 years) vs TEDRX (24 years). TEDRX (1.45) is less costly to investors than IGHSX (0.95). IGHSX is a more actively managed with annual turnover of: 67.00 vs. TEDRX (42.28). IGHSX has a lower initial minimum investment than TEDRX: IGHSX (0) vs TEDRX (1000). TEDRX (3.73) and IGHSX (3.62) have marching annual gain over last year. IGHSX return over 5 years is better than : 18.76 vs. TEDRX (-0.43).
IGHSXTEDRXIGHSX / TEDRX
Total Expense Ratio0.851.4559%
Annual Report Gross Expense Ratio0.951.4566%
Fund Existence18 years24 years-
Gain YTD3.4561.422243%
Front LoadN/AN/A-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets348M9.15B4%
Annual Yield % from dividends1.661.40118%
Returns for 1 year3.623.7397%
Returns for 3 years27.5614.80186%
Returns for 5 years18.76-0.43-4,356%
Returns for 10 years79.6315.15526%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LAC5.750.24
+4.36%
Lithium Americas Corp
WTBA23.970.38
+1.61%
West Bancorporation
LAFAU10.19N/A
N/A
Lafayette Acquisition Corp
WFCF11.92-0.12
-1.00%
Where Food Comes From
ARWR70.86-4.34
-5.77%
Arrowhead Pharmaceuticals